Abstract.
The surge in apoptosis research and the discovery of the phosphatidylserine binding properties of annexin A5 have propelled a tremendous interest in cell death detection technologies. In the past years, annexin A5 has evolved from an efficient assay for detection of apoptotic cells in vitro to an in vivo molecular imaging technology with potential clinical use. A second key discovery, the specific internalization properties of annexin A5, has opened the opportunity to use annexin A5 for therapeutic applications. Annexin A5-mediated internalization creates a novel therapeutic platform for targeted drug delivery and cell entry to treat various diseases, including cancer and cardiovascular disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
Received 29 June 2007; received after revision 19 July 2007; accepted 15 August 2007
Rights and permissions
About this article
Cite this article
Kenis, H., Hofstra, L. & Reutelingsperger, C.P.M. Annexin A5: shifting from a diagnostic towards a therapeutic realm. Cell. Mol. Life Sci. 64, 2859–2862 (2007). https://doi.org/10.1007/s00018-007-7297-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-007-7297-2